Analytical and clinical performance of newly developed immunoassay for detecting thyroid-stimulating immunoglobulin, the Immulite TSI assay

Jin Ju Kim, Soon Ho Jeong, Byungkwang Kim, Dokyun Kim, Seok Hoon Jeong

Research output: Contribution to journalArticle

Abstract

Graves’ disease (GD) is caused by autoantibodies against the thyrotropin receptor (TRAb), and among the three types of TRAbs, only the stimulating type (TSI) is known to be associated with GD. In this study, we evaluated the analytical performance of a new fully automated chemiluminescent TSI immunoassay, namely, the Immulite TSI assay, and compared the diagnostic efficacy of the assay with the Elecsys Anti-TSH receptor (TSHR) assay. Precision was evaluated using two levels of quality control reagents, and linearity was evaluated across the expected analytical measurement range (0.18–37.35 IU/L) at five levels using clinical samples. A comparative evaluation between the two assays was performed using 187 clinical samples, and the concordance of qualitative results was also assessed. The repeatability and total imprecision (% coefficient of variation) of the Immulite TSI assay were 3.19% and 3.46% at 0.93 IU/L, and 3.76% and 5.42% at 19.3 IU/L, respectively. The linearity of this assay ranged from 0.16 to 6.17 IU/L. A high degree of correlation was observed between quantitative values from each assay (correlation coefficient = 0.819). Moderate agreement between methods was observed with an overall qualitative agreement of 93.0%. Among 13 cases with discordant qualitative results, the Immulite TSI assay generated more favorable results consistent with clinical diagnoses of patients than the Elecsys Anti-TSHR assay. The Immulite TSI assay showed reliable analytical performance and good correlation with the Elecsys Anti-TSHR assay and we expect this method will be helpful for clinicians to evaluate patients with hyperthyroidism.

Original languageEnglish
Pages (from-to)443-448
Number of pages6
JournalScandinavian Journal of Clinical and Laboratory Investigation
Volume79
Issue number6
DOIs
Publication statusPublished - 2019 Aug 18

Fingerprint

Thyroid-Stimulating Immunoglobulins
Thyrotropin Receptors
Immunoassay
Assays
Graves Disease
Hyperthyroidism
Quality Control
Autoantibodies
Quality control

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry

Cite this

@article{1d628b26603448e289aced7ad121ad2d,
title = "Analytical and clinical performance of newly developed immunoassay for detecting thyroid-stimulating immunoglobulin, the Immulite TSI assay",
abstract = "Graves’ disease (GD) is caused by autoantibodies against the thyrotropin receptor (TRAb), and among the three types of TRAbs, only the stimulating type (TSI) is known to be associated with GD. In this study, we evaluated the analytical performance of a new fully automated chemiluminescent TSI immunoassay, namely, the Immulite TSI assay, and compared the diagnostic efficacy of the assay with the Elecsys Anti-TSH receptor (TSHR) assay. Precision was evaluated using two levels of quality control reagents, and linearity was evaluated across the expected analytical measurement range (0.18–37.35 IU/L) at five levels using clinical samples. A comparative evaluation between the two assays was performed using 187 clinical samples, and the concordance of qualitative results was also assessed. The repeatability and total imprecision ({\%} coefficient of variation) of the Immulite TSI assay were 3.19{\%} and 3.46{\%} at 0.93 IU/L, and 3.76{\%} and 5.42{\%} at 19.3 IU/L, respectively. The linearity of this assay ranged from 0.16 to 6.17 IU/L. A high degree of correlation was observed between quantitative values from each assay (correlation coefficient = 0.819). Moderate agreement between methods was observed with an overall qualitative agreement of 93.0{\%}. Among 13 cases with discordant qualitative results, the Immulite TSI assay generated more favorable results consistent with clinical diagnoses of patients than the Elecsys Anti-TSHR assay. The Immulite TSI assay showed reliable analytical performance and good correlation with the Elecsys Anti-TSHR assay and we expect this method will be helpful for clinicians to evaluate patients with hyperthyroidism.",
author = "Kim, {Jin Ju} and Jeong, {Soon Ho} and Byungkwang Kim and Dokyun Kim and Jeong, {Seok Hoon}",
year = "2019",
month = "8",
day = "18",
doi = "10.1080/00365513.2019.1658216",
language = "English",
volume = "79",
pages = "443--448",
journal = "Scandinavian Journal of Clinical and Laboratory Investigation",
issn = "0036-5513",
publisher = "Informa Healthcare",
number = "6",

}

Analytical and clinical performance of newly developed immunoassay for detecting thyroid-stimulating immunoglobulin, the Immulite TSI assay. / Kim, Jin Ju; Jeong, Soon Ho; Kim, Byungkwang; Kim, Dokyun; Jeong, Seok Hoon.

In: Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 79, No. 6, 18.08.2019, p. 443-448.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Analytical and clinical performance of newly developed immunoassay for detecting thyroid-stimulating immunoglobulin, the Immulite TSI assay

AU - Kim, Jin Ju

AU - Jeong, Soon Ho

AU - Kim, Byungkwang

AU - Kim, Dokyun

AU - Jeong, Seok Hoon

PY - 2019/8/18

Y1 - 2019/8/18

N2 - Graves’ disease (GD) is caused by autoantibodies against the thyrotropin receptor (TRAb), and among the three types of TRAbs, only the stimulating type (TSI) is known to be associated with GD. In this study, we evaluated the analytical performance of a new fully automated chemiluminescent TSI immunoassay, namely, the Immulite TSI assay, and compared the diagnostic efficacy of the assay with the Elecsys Anti-TSH receptor (TSHR) assay. Precision was evaluated using two levels of quality control reagents, and linearity was evaluated across the expected analytical measurement range (0.18–37.35 IU/L) at five levels using clinical samples. A comparative evaluation between the two assays was performed using 187 clinical samples, and the concordance of qualitative results was also assessed. The repeatability and total imprecision (% coefficient of variation) of the Immulite TSI assay were 3.19% and 3.46% at 0.93 IU/L, and 3.76% and 5.42% at 19.3 IU/L, respectively. The linearity of this assay ranged from 0.16 to 6.17 IU/L. A high degree of correlation was observed between quantitative values from each assay (correlation coefficient = 0.819). Moderate agreement between methods was observed with an overall qualitative agreement of 93.0%. Among 13 cases with discordant qualitative results, the Immulite TSI assay generated more favorable results consistent with clinical diagnoses of patients than the Elecsys Anti-TSHR assay. The Immulite TSI assay showed reliable analytical performance and good correlation with the Elecsys Anti-TSHR assay and we expect this method will be helpful for clinicians to evaluate patients with hyperthyroidism.

AB - Graves’ disease (GD) is caused by autoantibodies against the thyrotropin receptor (TRAb), and among the three types of TRAbs, only the stimulating type (TSI) is known to be associated with GD. In this study, we evaluated the analytical performance of a new fully automated chemiluminescent TSI immunoassay, namely, the Immulite TSI assay, and compared the diagnostic efficacy of the assay with the Elecsys Anti-TSH receptor (TSHR) assay. Precision was evaluated using two levels of quality control reagents, and linearity was evaluated across the expected analytical measurement range (0.18–37.35 IU/L) at five levels using clinical samples. A comparative evaluation between the two assays was performed using 187 clinical samples, and the concordance of qualitative results was also assessed. The repeatability and total imprecision (% coefficient of variation) of the Immulite TSI assay were 3.19% and 3.46% at 0.93 IU/L, and 3.76% and 5.42% at 19.3 IU/L, respectively. The linearity of this assay ranged from 0.16 to 6.17 IU/L. A high degree of correlation was observed between quantitative values from each assay (correlation coefficient = 0.819). Moderate agreement between methods was observed with an overall qualitative agreement of 93.0%. Among 13 cases with discordant qualitative results, the Immulite TSI assay generated more favorable results consistent with clinical diagnoses of patients than the Elecsys Anti-TSHR assay. The Immulite TSI assay showed reliable analytical performance and good correlation with the Elecsys Anti-TSHR assay and we expect this method will be helpful for clinicians to evaluate patients with hyperthyroidism.

UR - http://www.scopus.com/inward/record.url?scp=85071327984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071327984&partnerID=8YFLogxK

U2 - 10.1080/00365513.2019.1658216

DO - 10.1080/00365513.2019.1658216

M3 - Article

C2 - 31453725

AN - SCOPUS:85071327984

VL - 79

SP - 443

EP - 448

JO - Scandinavian Journal of Clinical and Laboratory Investigation

JF - Scandinavian Journal of Clinical and Laboratory Investigation

SN - 0036-5513

IS - 6

ER -